Aspire Biopharma Holdings, Inc. recently announced the signing of a Securities Purchase Agreement with a group of investors. Under this agreement, Aspire Biopharma sold notes amounting to $9,687,500 for a subscription price of $7,750,000. The notes, which feature a 20% original issue discount and no interest rate, will mature on February 19, 2026. Additionally, the notes can be converted into common stock starting 31 days from issuance at 80% of the lowest closing price within the preceding five trading days. The company retains the option to prepay these notes at a 20% premium to the principal amount.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-025257), on August 22, 2025, and is solely responsible for the information contained therein.